

THE LANCET

Microbe

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. *Lancet Microbe* 2021; published online April 20. [https://doi.org/10.1016/S2666-5247\(21\)00069-0](https://doi.org/10.1016/S2666-5247(21)00069-0).

Appendix

Table 1. Relative risk, relative risk reduction, absolute risk reduction and numbers needed to treat with 95% confidence intervals from publicly-available information.

Table 2. Calculations

Supplementary table 1.

| Company | vaccine arms | Relative risk | | | | | | Vaccine efficacy: relative risk reduction | | | | Absolute risk reduction | | | | Numbers needed to vaccinate | | | | |
|------------------------------|------------------------|---------------|-------|---------|--------|--------|--------|---|--------|-------------|--------|-------------------------|--------|---------|--------|-----------------------------|-----|---------|-------|-------|
| | | n | N | Risk | RR | SE(RR) | 95%LL | 95%UL | (RRR) | SE (RRR) | 95%LL | 95%UL | ARR | SE(ARR) | 95%LL | 95%UL | NNV | SE(NNV) | 95%LL | 95%UL |
| Pfizer/BioNTech | BNT162b2 mRNA | 8 | 18198 | 0.4396 | 0.0497 | 0.7096 | 0.0245 | 0.1011 | 95.03% | 0.14% | 89.89% | 97.55% | 0.0084 | 0.0014 | 0.0070 | 0.0098 | 119 | 0.0007 | 102 | 143 |
| | Placebo | 162 | 18325 | 8.8404 | | | | | | | | | | | | | | | | |
| Moderna/NIH | mRNA-1273 | 11 | 14134 | 0.7783 | 0.0592 | 0.6078 | 0.0322 | 0.1087 | 94.08% | 0.19% | 89.13% | 96.78% | 0.0124 | 0.0019 | 0.0104 | 0.0143 | 81 | 0.0010 | 70 | 96 |
| | Placebo | 185 | 14073 | 13.1457 | | | | | | | | | | | | | | | | |
| Gamaleya | GamCovidVac | 13 | 14094 | 0.9224 | 0.0903 | 0.6133 | 0.0489 | 0.1667 | 90.97% | 0.29% | 83.33% | 95.11% | 0.0093 | 0.0029 | 0.0063 | 0.0122 | 108 | 0.0015 | 82 | 158 |
| | Placebo | 47 | 4601 | 10.2152 | | | | | | | | | | | | | | | | |
| Johnson & Johnson | Ad26.COV2.S | 116 | 19514 | 5.9445 | 0.3338 | 0.2092 | 0.2708 | 0.4115 | 66.62% | 0.21% | 58.85% | 72.92% | 0.0119 | 0.0021 | 0.0097 | 0.0140 | 84 | 0.0011 | 71 | 103 |
| | Placebo | 348 | 19544 | 17.8060 | | | | | | | | | | | | | | | | |
| AstraZeneca/Oxford | ChAdOx1 nCov-19 | 37 | 5807 | 6.3716 | 0.3316 | 0.3699 | 0.2291 | 0.4800 | 66.84% | 0.41% | 52.00% | 77.09% | 0.0128 | 0.0041 | 0.0088 | 0.0169 | 78 | 0.0021 | 59 | 114 |
| | Placebo | 112 | 5829 | 19.2143 | | | | | | | | | | | | | | | | |

Data source:

| Company | vaccine | source | ref. |
|--------------------|-----------------|----------|------|
| Pfizer/BioNTech | BNT162b2 mRNA | table 2 | 2 |
| Moderna/NIH | mRNA-1273 | figure 4 | 3 |
| Gamaleya | GamCovidVac | table 2 | 5 |
| Johnson & Johnson | Ad26.COV2.S | table 10 | 8 |
| AstraZeneca/Oxford | ChAdOx1 nCov-19 | table 2 | 4 |

Supplementary Table 2.

| | diseased | healthy | All |
|-------------|----------|---------|-----|
| Exposed | a | b | n1 |
| Not exposed | c | d | n2 |
| All | | | |

$$\text{Relative risk : } RR = \frac{a/n_1}{c/n_2}$$

$$\text{Confidence intervals of RR : } 95\%CI = e^{Ln(RR) \pm 1.96 * SE} \text{ where } SE = \sqrt{\frac{b/a}{n_1} + \frac{d/c}{n_2}}$$

$$\text{Relative Risk Reduction: } RRR = 1 - RR$$

$$\text{Confidence intervals of RRR : } 95\%CI = 1 - 95\%CI RR$$

$$\text{Absolute Risk Reduction: } aRR = \frac{c}{n_2} - \frac{a}{n_1}$$

$$\text{Confidence Intervals of aRR: } 95\%CI = aRR \pm 1.96 * SE \text{ where } SE =$$

$$\sqrt{\frac{a/n_1 \times (1-a/n_1)}{n_1} + \frac{c/n_2 \times (1-c/n_2)}{n_2}}$$

$$\text{Number Needed to Vaccine: } NNV = \frac{1}{aRR}$$

$$\text{Confidence Intervals of NNV: } 95\%CI = \frac{1}{95\%CI aRR}$$